Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025

Core Insights - CorMedix Inc. is recognized as a promising investment opportunity, with a reaffirmed Buy rating due to strong revenue from DefenCath and growth catalysts like Rezzayo and TPN Phase 3 data expected in 2026 [1][2] - The company reported robust third-quarter results, achieving $104.3 million in net revenue and $130.8 million in pro forma net revenue, primarily driven by increased utilization of DefenCath among outpatient dialysis customers [2][3] - CorMedix returned to profitability with a net income of $108.6 million, or $1.26 per share, a significant improvement from a net loss of $2.8 million, or $0.05 per share, in the same quarter last year [3] - The company has raised its full-year 2025 pro forma net revenue forecast to between $390 million and $410 million, with net revenue expectations of $115 million to $135 million, bolstered by anticipated synergies of $30 million from the Melinta Therapeutics acquisition [4] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for infectious and inflammatory diseases, with its lead product being DefenCath, an antimicrobial catheter lock solution aimed at preventing catheter-related bloodstream infections in hemodialysis patients [5]